Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We had been near-term bullish on the S&amp;P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral</li>
<li>The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here</li>
<li>Still, our intermediate-term outlook remains bullish (as of 5/14/25 report), and we'll maintain our bullish intermediate-term view as long as market dynamics remain constructive and the SPX is above 6200</li>
</ul>


We had been near-term bullish on the S&amp;P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral
The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here
Still, our intermediate-term outlook remains bullish (as of 5/14/25 report), and we'll maintain our bullish intermediate-term view as long as market dynamics remain constructive and the SPX is above 6200


Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Gilead Sciences' third quarter of 2025 results demonstrate mixed performance across the company’s diverse portfolio, characterized by both significant growth in certain segments and challenges in others.</li><li>The HIV therapy segment remains a stronghold for Gilead, seeing expanding revenues with products like Biktarvy and Descovy demonstrating year-over-year growth of 6% and 20%, respectively.</li><li>Notably, Biktarvy achieved a record U.S. market share, highlighting robust demand driven by the company's commercial execution.</li></ul>

Gilead Sciences' third quarter of 2025 results demonstrate mixed performance across the company’s diverse portfolio, characterized by both significant growth in certain segments and challenges in others.The HIV therapy segment remains a stronghold for Gilead, seeing expanding revenues with products like Biktarvy and Descovy demonstrating year-over-year growth of 6% and 20%, respectively.Notably, Biktarvy achieved a record U.S. market share, highlighting robust demand driven by the company's commercial execution.

Gilead Sciences Unveils Game-Changing PrEP Strategy—Inside the Yeztugo Breakthrough!

Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Gilead's durable and highly profitable HIV franchise, led by Biktarvy, provides a stable cash flow foundation, funding shareholder returns and strategic investments into higher-growth areas.</li>
  <li>The strategic pivot to oncology, through acquisitions like Immunomedics (Trodelvy) and Kite Pharma (cell therapy), is the central pillar of the company's long-term growth strategy, aiming to diversify revenue streams ahead of eventual HIV patent cliffs.</li>
  <li>Key risks include increasing competition in the HIV market from long-acting injectables, the inherent clinical trial and regulatory risks in its oncology pipeline, and ongoing legal challenges and scrutiny over drug pricing and patent strategies.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Gilead's durable and highly profitable HIV franchise, led by Biktarvy, provides a stable cash flow foundation, funding shareholder returns and strategic investments into higher-growth areas.
  The strategic pivot to oncology, through acquisitions like Immunomedics (Trodelvy) and Kite Pharma (cell therapy), is the central pillar of the company's long-term growth strategy, aiming to diversify revenue streams ahead of eventual HIV patent cliffs.
  Key risks include increasing competition in the HIV market from long-acting injectables, the inherent clinical trial and regulatory risks in its oncology pipeline, and ongoing legal challenges and scrutiny over drug pricing and patent strategies.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Gilead Sciences  (GILD UW) - Sep 2025

<ul><li>Gilead Sciences has had a monumental few months, delivering one of its most successful quarters in recent history.</li><li>The Q2 2025 earnings call underscored the strength of Gilead’s HIV franchise—buoyed by the FDA approval and early launch of Yeztugo (lenacapavir) for twice-yearly PrEP, the rising momentum in oncology (notably with Trodelvy), and a growing footprint in cell therapy.</li><li>But beneath the surface of this commercial momentum, a strategic pivot may be underway: Gilead is reportedly in advanced talks to acquire Interius BioTherapeutics.</li></ul>

Gilead Sciences has had a monumental few months, delivering one of its most successful quarters in recent history.The Q2 2025 earnings call underscored the strength of Gilead’s HIV franchise—buoyed by the FDA approval and early launch of Yeztugo (lenacapavir) for twice-yearly PrEP, the rising momentum in oncology (notably with Trodelvy), and a growing footprint in cell therapy.But beneath the surface of this commercial momentum, a strategic pivot may be underway: Gilead is reportedly in advanced talks to acquire Interius BioTherapeutics.

Gilead Sciences' Kite Makes $350M Gene Therapy Gamble — Meet Interius Biotherapeutics!

<ul><li>Gilead Sciences delivered a mixed performance in their latest financial results, reflecting both strengths and challenges across their portfolio.</li><li>The company reported overall product sales of $6.6 billion for the first quarter, a 1% decline year-over-year, primarily attributable to a significant decrease in sales of Veklury, a COVID-19 treatment, which was down 45%.</li><li>The core business, however, excluding Veklury, demonstrated growth with a 4% increase, driven largely by their HIV segment and liver disease treatments.</li></ul>

Gilead Sciences delivered a mixed performance in their latest financial results, reflecting both strengths and challenges across their portfolio.The company reported overall product sales of $6.6 billion for the first quarter, a 1% decline year-over-year, primarily attributable to a significant decrease in sales of Veklury, a COVID-19 treatment, which was down 45%.The core business, however, excluding Veklury, demonstrated growth with a 4% increase, driven largely by their HIV segment and liver disease treatments.

Gilead Sciences: Cell Therapy Adoption & Expansion to Strengthen Its Competitive Position n Its Domain!

United States

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases.  The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gilead Sciences (GILD US)

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

Coasting as We Stalk for Buying Opportunity; Downgrading Near-Term Outlook to Neutral, But Still Bullish Intermediate-Term $SPX $QQQ; Downgrading...

Vermilion Research

Gilead Sciences Unveils Game-Changing PrEP Strategy—Inside the Yeztugo Breakthrough!

Gilead Sciences' third quarter of 2025 results demonstrate mixed performance across the company’s diverse portfolio, characterized by both...

Baptista Research

Primer: Gilead Sciences (GILD UW) - Sep 2025

Gilead's durable and highly profitable HIV franchise, led by Biktarvy, provides a stable cash flow foundation, funding shareholder returns and...

αSK

Gilead Sciences' Kite Makes $350M Gene Therapy Gamble — Meet Interius Biotherapeutics!

Gilead Sciences has had a monumental few months, delivering one of its most successful quarters in recent history. The Q2 2025 earnings call...

Baptista Research

Gilead Sciences: Cell Therapy Adoption & Expansion to Strengthen Its Competitive Position n Its Domain!

Gilead Sciences delivered a mixed performance in their latest financial results, reflecting both strengths and challenges across their...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)